REGN · CUSIP 75886F107
Regeneron Pharmaceuticals, Inc.
Reported by 3 of 79 curated managers in Q2 2026, in the holdings snapshot last exported 2026-10-26.
- Managers holding
- 3
- Average portfolio weight
- 3.0%
- Combined reported value
- $3.2B
- Research group
- 79
3 of the 79 superinvestors Shameless Cloning tracks reported Regeneron Pharmaceuticals, Inc. (REGN) in their Q2 2026 13F filings, worth $3.2B combined, at an average 3.0% of their portfolios. The largest positions by portfolio weight belong to Mason Hawkins (5.0%), Harry Burn (2.4%), Dodge & Cox Funds (1.6%).
Reporting managers
This is a historical 13F snapshot, not a live shareholder register. The count covers all matched managers; dashboard rankings use only those with at least 95% coverage. Reported value is measured at filing quarter-end, not at today's price.
| Manager / SEC filer | % of portfolio | Reported value |
|---|---|---|
| Mason HawkinsSOUTHEASTERN ASSET MANAGEMENT INC/TN/ | 5.0% | $95.0M |
| Harry BurnSound Shore Management Inc /CT/ | 2.4% | $79.2M |
| Dodge & Cox FundsDodge & Cox | 1.6% | $3.0B |